Novartis has dropped a phase 2-stage radioligand therapy (RLT) after the candidate disappointed in the clinic. The Swiss pharma had been evaluating the gastrin-releasing peptide receptor ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued development in sickle cell disease (SCD), leading the company to ax an ...

San Diego-based Axiom Biosciences intends to go public via a listing on the Hong Kong Stock Exchange (HKEX) followed by a ...

For years, as Big Pharma poured billions into antibody-drug conjugates, Novartis CEO Vas Narasimhan notably stayed on the ...

Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for the U.S. rights to an MDMA drug to treat ...

India-based Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit ...

The nonprofit Center for Therapeutic Genetics (CTG) will have a small physical space at the Broad Institute of MIT and ...

Bristol Myers Squibb has touted its strengthened collaboration with Nvidia as aiming to build the “most powerful AI factory ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for ...